A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: The challenge of interpreting results of comprehensive mutational testing in lung cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 1, 2014, Pages 6-11

  Lammers, Philip E ^a   Lovly, Christine M ^a   Horn, Leora ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ORAL ANTIDIABETIC AGENT; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; THYROID TRANSCRIPTION FACTOR 1;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SIZE; CANCER STAGING; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPIDERMAL GROWTH FACTOR RECEPTOR L858R GENE; EPIDERMAL GROWTH FACTOR RECEPTOR T790M GENE; EXON; FAMILY HISTORY; FOLLOW UP; GENE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HEMOPTYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMAGE GUIDED BIOPSY; LUNG ADENOCARCINOMA; LUNG NODULE; MAINTENANCE THERAPY; MALE; MEDIASTINUM LYMPHADENOPATHY; MEDICAL HISTORY; MISSENSE MUTATION; MOTHER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA GENE; PLEURA EFFUSION; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; REPEAT PROCEDURE; SMOKING CESSATION; STAINING; THORAX RADIOGRAPHY; TUNNELED PLEURAL CATHETER;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PYRAZOLES; PYRIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84893783683     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0002     Document Type: Article

References (23)

1. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
2. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
3. Su Z, Dias-Santagata D, Duke M, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011;13:74-84.
4. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
5. Ettinger DS, Wood DE, Akerley W, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2, 2014. Available at: NCCN.org. Accessed December 3, 2013.
6. NCCN Biomarkers Compendium. National Comprehensive Cancer Network Web site. Available at: NCCN.org. Accessed December 3, 2013.
7. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870.
8. Bos M, Gardizi M, Schildhaus HU, et al. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013;81:142-143.
9. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 8009.
10. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012;7:e23-24.
11. De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123-127.
12. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-635.
13. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-384.
14. Mack PC, Holland WS, Burich RA, et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009;4:1466-1472.
15. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.
16. Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res 2012;22:2101-2108.
17. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010;28:4616-4620.
18. Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:707-715.
19. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012;11:485-491.
20. Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors. Presented at the 37th ESMO Congress; September 28-October 2, 2012; Vienna, Austria.
21. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-1316.
22. Girard N, Lou E, Azzoli CG, et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010;16:755-763.
23. Tibaldi C, Giovannetti E, Vasile E, et al. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol 2011;6:395-396.